Lipid Nanoparticles (LNPs) are promising non-viral delivery vehicles composed of a specific mixture of lipids including cationic/ionizable lipids, and other excipients.
A technology that has been in development for some time, the recent COVID-19 vaccines by companies such as Moderna and Pfizer have vaulted LNPs into the spotlight as critical delivery systems of nucleic acids ,especially messenger RNA (mRNA). This technology not only protects the payload but also overcomes multiple physiological barriers.
In addition to facilitating rapid vaccine development, LNPs are capable of carrying and delivering therapies that may be useful in a number of applications, including infectious disease, immuno-oncology, genetic disorders, and neurodegenerative conditions.
Traditionally, the use of cationic lipids may cause concerns regarding toxicity, however, the specific cationic lipid in use in this study is 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP), which is a widely used and tested lipid.
In this Application Note we explore how Microfluidizer® Technology plays a vital role in safely producing lipid nanoparticles.
.webp "Microfluidics-Logo-With-TM"){kind=logo}
